Fenestrated Anaconda Endograft (Vascutek) for Juxtarenal Aneurysm Repair and Type 1A Endoleaks: Advantages and European Multicenter Results to Date.

Donald B Reid MD FRCS
Scotland, UK
Clark J Zeebregts MD PhD
Holland
Afshin Assadian MD
Austria

Disclosures
• Consultant to Vascutek

Fenestrated Anaconda
Indications
Juxtarenal aneurysms
Short necks
(Type 1 endoleak patients)

Fenestrated Anaconda
First Case in June 2010
Now > 1,000 cases worldwide

Redeployment

Case Planning

Cannulation of Renal Arteries

Covered Stenting of Renal Artery

Left Renal Artery

Superior Mesenteric Artery
**Fenestrated Cuff for Type 1 Endoleaks**

628 Patients

Follow up at discharge & annually

**Fenestrated Anaconda Registry**

<table>
<thead>
<tr>
<th>Country</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>3  16</td>
</tr>
<tr>
<td>Belgium</td>
<td>6  28</td>
</tr>
<tr>
<td>Canada</td>
<td>6  21</td>
</tr>
<tr>
<td>France</td>
<td>13 64</td>
</tr>
<tr>
<td>Germany</td>
<td>26 138</td>
</tr>
<tr>
<td>Hungary</td>
<td>1  1</td>
</tr>
<tr>
<td>Italy</td>
<td>12 25</td>
</tr>
<tr>
<td>Monaco</td>
<td>1  6</td>
</tr>
<tr>
<td>Poland</td>
<td>1  1</td>
</tr>
<tr>
<td>Spain</td>
<td>4  17</td>
</tr>
<tr>
<td>Sweden</td>
<td>2  2</td>
</tr>
<tr>
<td>Switzerland</td>
<td>2  7</td>
</tr>
<tr>
<td>Netherlands</td>
<td>13  61</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>22  238</td>
</tr>
<tr>
<td>Totals</td>
<td>114 628</td>
</tr>
</tbody>
</table>

**Type of Endograft**

<table>
<thead>
<tr>
<th>Graft Type</th>
<th>Total UN (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bifurcate</td>
<td>584 (94.7%)</td>
</tr>
<tr>
<td>Cuff</td>
<td>20 (3.2%)</td>
</tr>
<tr>
<td>AUI</td>
<td>11 (1.8%)</td>
</tr>
<tr>
<td>Leg</td>
<td>2 (0.3%)</td>
</tr>
</tbody>
</table>

**Number of Fenestrations**

<table>
<thead>
<tr>
<th>Type</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bifurcate</td>
<td>-</td>
<td>33</td>
<td>292</td>
<td>193</td>
<td>65</td>
<td>1</td>
</tr>
<tr>
<td>Cuff</td>
<td>1</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AUI</td>
<td>1</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Leg</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Endoleaks

<table>
<thead>
<tr>
<th></th>
<th>Day 0</th>
<th>Discharge</th>
<th>1 Year</th>
<th>2 Year</th>
<th>3 Year</th>
<th>4 Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type I</td>
<td>40 10 1</td>
<td></td>
<td>4</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type II</td>
<td>37 11 3</td>
<td></td>
<td>3</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Type III</td>
<td>21 10 2</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Type IV</td>
<td>3 4 0</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>17 1 9</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mortality (30 day) 5.0 %
Visceral vessel occlusion (1 year) 1.4 %

Conclusions

Initial experience shows favourable clinical results
Long term follow up will be important